The invention discloses an OCTS-based CAR-T vector for treating spongioblastoma, consisting of lentiviral skeleton plasmid, human EF1α promoter (SEQ ID NO.14), OCTS chimeric receptor structural domain, and PDL1 single-chain antibody； the OCTS chimeric receptor structural domain consists of CD8 leader chimeric receptor signal peptide (SEQ ID NO.15), PDL1 single-chain antibody light chain VL (SEQ ID NO.16), PDL1 single-chain antibody heavy chain VH (SEQ ID NO.17), EGFRvIII single-chain antibody light chain VL (SEQ ID NO.18), EGFRvIII single-chain antibody heavy chain VH (SEQ ID NO.19), antibody Inner-Linker (SEQ ID NO.20), single-chain antibody Inter-Linker (SEQ ID NO.21), CD8 Hinge chimeric receptor linker (SEQ ID NO.22), CD8 Transmembrane chimeric receptor transmembrane domain (SEQ ID NO.23), TCR chimeric receptor T cell activation domain (SEQ ID N0.26) and chimeric receptor co-stimulator domain. Also, the invention discloses the preparation method and application in the preparation of drugs for treating spongioblastoma of the vector.
